Background: Stroke is the second most common cause of mortality and the third most common cause of disability. Modifiable risk factors for ischemic stroke include obesity, diabetes, hypertension, cigarette smoking, atrial fibrillation, dyslipidemia, carotid artery stenosis, sickle cell disease, postmenopausal hormone therapy, poor diet, and physical inactivity. There is data establishing the role of atherosclerosis in stroke. Evidence suggests a role for inflammation in the development of atherosclerosis and cerebrovascular disease. YKL-40, also called chitinase-3-like-1 (CHI3L1), is a novel inflammatory biomarker secreted by monocytes which has been elevated in stroke patients in multiple studies. Objective: The aim of this study was to assess if patients with elevated YKL-40 have increased odds of having a stroke. Methods: PubMed, Embase, CINAHL, Cochrane, Web of Science, and google scholar were searched using the keywords YKL-40, chitinase-3-like-1 (CHI3L1), human cartilage glycoprotein 39 (HC-gp39), stroke, ischemic stroke, cerebrovascular disease, atherosclerosis, and inflammation. English studies from 1960 to August 2017 addressing YKL-40 and stroke as well as YKL-40 levels in subjects with and without stroke were analyzed. YKL-40 levels were converted to ng/mL if provided in any other scale. Results: Ten studies met the inclusion criteria. Twelve datasets were analyzed, as 1 study included more than 1 dataset. Seven studies were case-control studies (n = 702 cases and n = 389 controls), while 3 studies were cross-sectional (n = 13,811). A random effects model was used. The standardized mean difference in YKL-40 levels between the stroke group and the control group was 2.21 (1.28-3.14, p < 0.001). Sensitivity analysis and cumulative analysis showed unchanged results. Funnel plots/precision plots indicated publication bias. Meta-regression analysis of case-control studies for the variables age and gender showed no significant impact of age (p = 0.33) and male gender (p = 0.11). Conclusion: High YKL-40 levels appear to be associated with stroke.
Introduction
Stroke is the second most common cause of mortality and the third most common cause of disability [1] . Although the overall rate of stroke-related mortality is decreasing, the absolute number of people with stroke, stroke-related deaths, and disability is increasing [2] . sity, diabetes, hypertension, cigarette smoking, atrial fibrillation, dyslipidemia, carotid artery stenosis, sickle cell disease, postmenopausal hormone therapy, poor diet, and physical inactivity [3] . There is data establishing a role for atherosclerosis in stroke [4] . Moreover, there is also evidence that inflammation plays an important role in the development of atherosclerosis [5] and cerebrovascular disease [6, 7] . Studies have documented elevated levels of inflammatory markers, such as serum C-reactive protein, to be a risk factor for ischemic stroke [8] . YKL-40, also called chitinase-3-like-1 (CHI3L1), is a novel inflammatory biomarker secreted by monocytes infiltrating the vessel wall with subsequent differentiation into lipidladen macrophages [9] . Data is becoming available documenting an association of YKL-40 elevation with coronary artery disease [10] , cardiovascular disease [11] , severity of cardiovascular disease, mortality [12] , and mortality from heart failure [13] . YKL-40 was also found to be elevated as a marker of inflammation, tissue-remodeling cancer [14] , and insulin resistance in diabetes [15] . Moreover, it was found to be elevated in multiple studies which are documenting its association with stroke. We performed a review and meta-analysis of these studies to explore this association.
Methods
This systematic review and meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We implemented a comprehensive literature search of 6 databases: PubMed, Embase, CINAHL, Cochrane, Web of Science, and google scholar from inception until June 2017 using the following keywords: "YKL-40" OR chitinase-3-like-1 (CHI3L1) [ (Fig. 1) . All studies provided data on YKL-40 levels in subjects with and without stroke. Data was extracted that was available in 2 forms; means and standard deviations (SD) of YKL-40 levels or odds of stroke in subjects with the highest quartile of YKL-40 levels against the lowest quartile of YKL-40 levels (as some studies provided only odd ratios but no mean and SD values of YKL-40) (Fig. 2) . If the data was in the form of a graph, then digitization software (http://plotdigitizer.sourceforge.net) was used to extract numerical data. If the values were presented as medians with confidence intervals, they were converted to means with SD by previously described methods [16] . All values of YKL-40 were converted to ng/mL if provided in any other scale.
Review of Cross-Sectional Studies
Three studies (Kjaergaard et al. [17, 18] and Rathcke et al. [19] ) with a total sample of 14,811 subjects compared the levels of YKL- Reviewing full text and applying inclusion criteria found 10 studies 40 (highest quartile vs. lowest quartile) in patients with and without stroke. All studies showed increased odds of stroke in patients with YKL-40 values in the highest quartile. Including these studies in the meta-analysis would only make the results more significant, as they all found higher odds of stroke in subjects with higher levels of YKL-40. Moreover, this data could not be included in the meta-analysis because of different methodologies.
Meta-Analysis of Case-Control Studies
Study selection, data extraction, and statistical analysis were all done in accordance with previously published methodology for meta-analyses (http://www.prisma-statement.org). Heterogeneity between included studies was assessed by I 2 statistics. An I 2 of 25-49% was considered to represent a low level of heterogeneity, 50-60% a moderate level, and 60-100% a high level. Standardized differences in means were calculated using a random effects model for all outcomes with > 60% heterogeneity (I 2 > 60) and a fixed effects model for I 2 < 60. The measurement unit of YKL-40 was ng/ mL. If any of these values were presented in other units, they were converted to ng/mL. YKL-40 levels were measured in all studies in serum, except in 1 study, where levels were measured in cerebrospinal fluid (Hjalmarsson et al. [20] ).
Statistical Analysis
All statistical analyses were done using Cochrane Review Manager version 5.1 and Comprehensive Meta-Analysis Software version 2 (Biostat, Englewood, NJ, USA). Meta-regression was also performed. Data from cross-sectional studies was not included in the meta-regression analysis, as provided data had already calculated odds ratios which were adjusted for age and male gender. Publication bias was assessed using multiple different methods to provide robust results. The methods included funnel plot analysis, Egger's regression intercept, and Kendall's tau with and without continuity correction.
Studies search resulted in 10 studies meeting the inclusion criteria. Characteristics of the studies are summarized in Table 1 . There were 12 datasets, as 1 study had more than 1 dataset (Table  1) : Xu et al. [21] provided 3 datasets, i.e., YKL-40 values in acute ischemic stroke, or in patients with acute hemorrhagic stroke, or in patients with transient ischemic attack. All data from the same study were analyzed, though.
Seven studies were case-control studies (n = 702 with stroke and n = 389 controls), while 3 studies were cross-sectional (n = 13,811). All case-control studies provided the levels of YKL-40 in both groups and confounding variables of age and gender percentages. The 3 cross-sectional studies provided odds ratios of having stroke while comparing YKL-40 levels in quartiles; they compared the highest quartiles to the lowest quartiles. These odds ratios were already adjusted for variables, i.e., age and gender. The results of these studies were tabulated, while we performed a meta-analysis and meta-regression of case-control studies.
Results
We found significant heterogeneity (I 2 > 66%) in the included studies; therefore, a random effects model was used. The standardized mean difference in YKL-40 levels between the stroke group and the control group was 2.21 (1.28-3.14, p < 0.001) (Fig. 2) . Sensitivity analysis while removing 1 study at a time (Fig. 3) and cumulative analysis were performed, and results remained unchanged. Sensitivity analysis for I 2 showed in general high heterogeneity, although the study by Jiang et al. [22] affected heterogeneity the most by the highest I 2 value. Funnel plots/precision plots indicated a publication bias in the meta-analysis (Fig. 4) .
Meta-regression analysis for case-control studies for the variables age and male gender showed no significant impact (age, p = 0.33; Fig. 5 ; male gender, p = 0.11; Fig. 6 ). 
Discussion
Our analysis showed that the standardized mean difference in YKL-40 levels between the stroke group and the control group was 2.21 (1.28-3.14, p < 0.001). Evidence is growing that suggests a role for inflammation in the pathogenesis of stroke. C-reactive protein has been found to be elevated in patients with stroke [23] . YKL-40 is a biomarker of inflammation, associated with both acute and chronic inflammation with a role in cell differentiation, protection against apoptosis, and tissue remodeling [24] . YKL-40 was found to be associated with diseases involving inflammation, i.e., asthma [25] , rheumatoid arthritis, systemic lupus erythematosus [26] , and inflammatory bowel disease [27] . Moreover, YKL-40 was found to be most useful in cardiovascular diseases as a marker of disease severity, prognosis, and short survival [13] . Serum YKL-40 is significantly associated with all-cause mortality in patients with heart failure and could potentially be a new prognostic biomarker in these patients [28] . It is associated with inflammation and severity of intracerebral hemorrhage and may independently predict long-term clinical outcomes of intracerebral hemorrhage [22] . Some cancer patients with breast cancer [29] and gliomas [30] also showed high serum levels of YKL-40. For metastatic breast cancer, YKL-40 is an independent prognostic variable for disease progression and death [31] . On the contrary, there are no studies on serum YKL-40 levels in patients with benign diseases of the intestine, breast, and kidney.
The mechanism behind the association of YKL-40 with stroke can only be postulated based on available indirect evidence, as there are no large-size multicenter prospective trials available. One can hypothesize that ischemic stroke is the end result of vascular stenosis, which is a result of vascular atherosclerosis. Atherosclerosis is accelerated or promoted by inflammation, which is again a multifactorial process. YKL-40 is a biomarker which is elevated as a result of this augmented inflammation. It is a biomarker secreted by monocytes infiltrating the vessel wall with subsequent differentiation into lipidladen macrophages; therefore, we believe it augments local inflammatory activity with subsequent attraction of further deposition of monocytes and lipids [9] . Only future studies will determine if it is a cause or effect of inflammation. Data is also required to assess whether YKL-40 has any specific causal role in ischemic stroke or whether it is a nonspecific factor, as it is elevated in a variety of disorders [32] . It may just be a marker of organ dysfunction [33] .
Our meta-analysis has the following weaknesses; only few studies are available, and most are either case-control or cross-sectional studies. Therefore, this analysis provides weak evidence for an association of YKL-40 with stroke. We found significant heterogeneity (I 2 > 66%) in the included studies; therefore, a random effects model was used. Meta-regression of case-control studies (n = 7) included a very small sample to assess the impact of confounding factors, although evidence already exists that age and gender are significant risk factors for stroke. Funnel plots also suggest a significant publication bias. Nevertheless, the meta-analysis suggests this association and emphasizes that larger studies are needed to define the role of YKL-40 levels in subjects with stroke.
Conclusion
There appears to be an association between stroke and elevated YKL-40 levels. Larger studies are needed to explore the role of YKL-40 levels as a marker for disease activity in stroke.
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